📖
Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).
Liang J, Bo L, Miao X, Guo X, Xu J, He J, Ye X

Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in BMC Pharmacol Toxicol.

Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).
Author / Organization Liang J, Bo L, Miao X, Guo X, Xu J, He J, Ye X
Subject & Discipline BMC Pharmacol Toxicol
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-137393
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »